Table 1.
Demographics pwMS and pwNIc who received a specialist consultation to discuss tixagevimab/cilgavimab access
| All pwMS and pwNIc who received tixagevimab/cilgavimab access consultation | pwMS and pwNIc who consented to tixagevimab/cilgavimab but failed to secure administration | pwMS and pwNIc who received tixagevimab/cilgavimab appointment but declined or were ineligible | |
| Total n=233 |
Total n=47 |
Total n=13 |
|
| Age (years) | |||
| Min | 18 | 29 | 24 |
| Max | 84 | 70 | 73 |
| Mean | 49.90 | 48.13 | 51.85 |
| Sex n (%) | |||
| Female | 169 (72.5%) | 32 (68%) | 7 (53.85%) |
| EDSS | |||
| Min | 0 | 0 | 1 |
| Max | 9 | 7.5 | 9 |
| Mean | 3.31 | 2.84 | 5.1 |
| DMT treatment n (%) | |||
| Ocrelizumab | 168 (72.10%) | 34 (72.34%) | 10 (76.92%) |
| Ofatumumab | 11 (4.72%) | 3 (6.38%) | 1 (7.69%) |
| Rituximab | 10 (4.29%) | 0 | 1 (7.69%) |
| Fingolimod | 29 (12.45%) | 7 (14.89%) | 0 |
| Siponimod | 7 (3.0%) | 1 (2.12%) | 1 (7.69%) |
| Other | 6 (2.58%) | 1 (2.12%) 1 missing data | 0 |
| COVID-19 Vaccine dose no n (%) | |||
| 2 | 19 (8.15%) | 9 (19.14%) 1 missing data | 2 (15.38%) |
| 3 | 63 (27.03%) | 11 (23.40%) | 1 (7.69%) |
| 4 | 111 (47.64%) | 25 (53.19%) | 6 (46.15%) |
| 5 | 38 (16.31) | 1 (2.13%) | 4 (30.77%) |
| Reason for not proceeding with tixagevimab/cilgavimab | |||
| Cardiac ineligible | 4 (30.77%) | ||
| Patient assessment of risk/benefit | 8 (61.54%) | ||
| Previous vaccine reaction | 1 (7.69%) | ||
DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale Score; pwMS, people with multiple sclerosis; pwNIc, people with neuroimmunological conditions.